How much funding has Cambridge Epigenetix raised?

Cambridge Epigenetix has raised $144.5M in total funding, most recently a Series A round.

Who are Cambridge Epigenetix's investors?

Cambridge Epigenetix's investors include New Science Ventures, GV, Ahren Innovation Capital, Temasek, Sequoia Capital, Syncona Partners.

When was Cambridge Epigenetix founded?

Cambridge Epigenetix was founded in 2012.

Where is Cambridge Epigenetix headquartered?

Cambridge Epigenetix is headquartered in London, England, United Kingdom.

What industry is Cambridge Epigenetix in?

Cambridge Epigenetix operates in Biotech, Healthcare, Medical.

How many employees does Cambridge Epigenetix have?

Cambridge Epigenetix has 11-50 employees.

Cambridge Epigenetix

cambridge-epigenetix

London, United Kingdom · Founded 2012 · $144.5M raised

Biotech

Healthcare

Medical

Headquarters: London, England
Employees: 11–50
Founded: 2012
Business Model: B2B

Website: cambridge-epigenetix.com
Total Funding: $144.5M
Last Round: $5.5M Series ANov 2021
Rounds: 4

About

Cambridge Epigenetix (now rebranded as biomodal) is a life sciences tools company revolutionizing genome sequencing by enabling simultaneous genetic and epigenetic analysis from a single DNA sample. Its duet multiomics platform distinguishes multiple cytosine modifications to provide a 6-base genome view, enabling earlier and more accurate detection of cancer and other diseases through liquid biopsy and research applications.

Summary

Cambridge Epigenetix is a Biotech company based in London, United Kingdom, founded in 2012. It has raised $144.5M in total across 4 rounds, most recently a $5.5M Series A round in Nov 2021. Investors include New Science Ventures, GV and Ahren Innovation Capital.